Health

GSK CEO Optimistic About Dealmaking, Trump Administration

Emma Walmsley says more deals should be expected after IDRx
GSK worked well with previous Trump administration: CEO

Emma Walmsley
Photographer: Vivian Wan/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Ashleigh Furlong, Antonia Mufarech, and Katie Greifeld

January 13, 2025 at 7:15 PM UTC

Updated on

January 14, 2025 at 8:10 AM UTC

This article is for subscribers only.

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines.

While GSK already agreed to multiple deals in 2024 and announced an agreement for cancer biotech IDRx Inc. for as much as $1.15 billion on Monday, “you should expect more from us,” Walmsley said in an interview with Bloomberg TV.